Chemical inhibition of alpha-toxin, a key corneal virulence factor of Staphylococcus aureus.

Investigative Ophthalmology & Visual Science
Clare C McCormickRichard J O'Callaghan

Abstract

alpha-Toxin mediates extreme corneal damage during Staphylococcus aureus keratitis. Chemical inhibition of this toxin was sought to provide relief from toxin-mediated pathology. Inhibition of alpha-toxin by phosphate-buffered saline (PBS), 0.1% methyl-beta-cyclodextrin (CD), or CD plus cholesterol (0.1%, CD-cholesterol) was assayed by hemolysis of rabbit erythrocytes. Pathologic changes in rabbit corneas injected with 12 hemolytic units of alpha-toxin suspended in PBS, 1% CD, or 1% CD-cholesterol were compared over time. Rabbit corneas injected with 10(2) colony forming units (CFU) of S. aureus were treated from 7 to 13 hours postinfection (PI) with a total of 15 drops of CD-cholesterol, CD, or PBS. Slit lamp examination (SLE) and measurement of erosions were performed at 13 hours PI and bacteria were quantified at 14 hours PI. Toxin-mediated lysis of erythrocytes was inhibited up to 16,000-fold in the presence of CD-cholesterol compared with CD or PBS. Eyes injected with alpha-toxin mixed with CD-cholesterol had, at 7 hours postinjection, significantly smaller erosions than eyes injected with alpha-toxin in PBS or alpha-toxin mixed with CD (P = 0.0090 and P = 0.0035, respectively). Eyes infected with S. aureus and treated with...Continue Reading

Citations

Nov 4, 2010·Advances in Therapy·Charles L BalzliRichard J O'Callaghan
Apr 16, 2013·Nature Nanotechnology·Che-Ming J HuLiangfang Zhang
Dec 4, 2010·The Journal of Biological Chemistry·Atsuko HayashidaPyong Woo Park
Oct 7, 2009·Antimicrobial Agents and Chemotherapy·Brook E RagleJuliane Bubeck Wardenburg
Jan 8, 2011·Journal of Integrative Neuroscience·Kevin C ChanEd X Wu
Jan 29, 2011·Journal of Biomedicine & Biotechnology·Mary E Marquart
Feb 1, 2013·Journal of Ophthalmology·Mary E Marquart, Richard J O'Callaghan
Jun 10, 2014·Ocular Immunology and Inflammation·Armando R CaballeroRichard J O'Callaghan
Oct 1, 2014·Current Eye Research·Angela M AranaRichard J O'Callaghan
Oct 7, 2011·Journal of Applied Microbiology·J WangX Deng
May 12, 2010·Veterinary Anaesthesia and Analgesia·Masoud Selk Ghaffari, Amir P Moghaddassi
Nov 5, 2011·Current Eye Research·Anastasia C WeeksRichard O'Callaghan
Aug 24, 2010·Vision Research·Luis Alarcón-MartínezManuel Vidal-Sanz
Jun 1, 2016·Frontiers in Cellular and Infection Microbiology·Emilia BonarBenedykt Wladyka
Jan 12, 2013·PloS One·Sivagnanam AnanthiKuppamuthu Dharmalingam
Jul 31, 2013·Visual Neuroscience·David M Hunt, Leo Peichl
Feb 1, 2017·Drug and Chemical Toxicology·Faqir MuhammadSantosh Aryal
Jan 11, 2018·Pathogens·Richard J O'Callaghan
Jan 7, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Weiwei GaoLiangfang Zhang
Sep 18, 2020·Current Eye Research·Armando R CaballeroMary Marquart
Apr 5, 2020·International Journal of Molecular Sciences·Marialaura MarchettiLuca Ronda
Sep 25, 2019·Toxins·Neža OmersaGregor Anderluh
Jul 18, 2018·Proceedings of the National Academy of Sciences of the United States of America·Peng GaoRichard Yi Tsun Kao
Aug 31, 2021·The Ocular Surface·Lawson Ung, James Chodosh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.